From sequence to data: Accelerating antibody discovery with TurboCHO 3.0 and AI-driven biologics validation
Thursday, September 3 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
The rapid evolution of AI-driven drug discovery (AIDD) is transforming antibody research, enabling the generation of larger candidate pools and more complex biologics than ever before. However, the speed of biological validation has become a critical bottleneck in the Design-Build-Test-Learn (DBTL) workflow.
In this SelectScience® webinar, we will explore how GenScript's upgraded TurboCHO™ 3.0 expression platform and integrated AIDD solutions help researchers accelerate the journey from DNA sequence to actionable decision-making.
Attendees will learn how high-throughput protein expression, multi-platform validation, automation, and AI-ready data generation can improve screening efficiency, support complex antibody modalities, and enable faster, data-driven discovery of next-generation biologics.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
Speakers
Moderator
Who should attend?
- Professionals in biopharmaceuticals
- Biopharmaceutical contract research organizations (CROs)
- Antibody discovery professionals
- Antibody engineering professionals
- Protein expression specialists
- Biologic developers
- R&D managers
Featured products
Request Quote for All Products
TurboCHO™ High Throughput Platform
GenScriptFrom Gene Synthesis to Delivery as Fast as 5 Business Days
What will this webinar cover?
- The emerging challenges and opportunities in AI-driven antibody discovery and the evolving DBTL workflow.
- GenScript's integrated AIDD workflow, including high-throughput expression, multi-platform protein production, and comprehensive characterization services.
- How AI-ready experimental data can accelerate model iteration and enable faster, evidence-based decision-making in biologics discovery.
Join the webinar to get answers to these questions:
- How is AI-driven drug discovery reshaping antibody research and the DBTL workflow?
- What challenges arise when scaling AI-driven antibody discovery, and how can they be addressed?
- How does GenScript’s TurboCHO™ 3.0 and integrated AIDD workflow accelerate protein expression and validation?
- In what ways can multi-platform validation and automation improve screening efficiency for complex biologics?
- How can AI-ready experimental data speed model iteration and support faster, evidence-based decisions in biologics discovery?